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A pandemic coronavirus disease of 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has now been declared a global pandemic by the World
Health Organization. The search for new drugs, especially by utilizing antiviral peptides is a very
potential area. Through this study, protein-peptide docking and protein-protein docking simulations
were conducted using in silico methods to identify, evaluate, and explore the molecular affinity
and interaction of dermaseptin peptide molecules produced by frogs of the genus Phyllomedusa
against the SARS-CoV-2 spike protein macromolecule, and its effect on attachment to the surface
of the ACE-2 (Angiotensin Converting Enzyme-2) receptor. Protein-peptide docking simulation
results show that dermaseptin-S9 peptide molecule has the best affinity to the active site of SARSCoV-2 spike protein macromolecule binding site, with a binding free energy value of −792.93
kJ/mol. Then the results of protein-protein docking simulations proved that dermaseptin-S9
peptide molecule was able to prevent the attachment of SARS-CoV-2 spike protein to the surface
of the ACE-2 receptor, with a total energy value of 517.85 kJ/mol. Therefore, it is hoped that
dermaseptin-S9 peptide molecule can be further studied in the development of novel antiviral
peptide candidates for the control of COVID-19 infectious disease.
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INTRODUCTION
The World Health Organization has now declared a
global emergency and a pandemic for novel coronavirus
disease of 2019 (COVID-19, formerly called 2019nCoV) which has been actively spreading throughout the
world. The COVID-19 infectious disease caused by the
SARS-CoV-2 virus can cause symptoms such as fever,
cough, pneumonia, nausea, and fatigue. To date, SARSCoV-2 has spread to almost 24 countries worldwide
and more than 8,061,550 people have been reported to
be infected by 17 June 2020. Among these, there have
been 440,290 deaths reported to be related to COVID-19
(Gabutti et al., 2020).
The main epidemiological cause of the SARS-CoV-2
virus is thought to originate from the seafood market in
Wuhan City, Hubei Province, China (Chen et al., 2020).
However, the true center of the initial transfer to humans
is still unknown. At present, there are more than 100
complete genome sequences known in NCBI GenBank
obtained from approximately 10 countries. Later it was
also found that the variation between these sequences
was less than 1% (Lu et al., 2020; Sah et al., 2020).
The SARS-CoV-2 virus is closely related to SARS-CoV
and this allows the use of a known protein structure
to quickly study models to find candidate compounds

in the prevention and treatment of this SARS-CoV-2
virus (Hui et al., 2020). While traditional methods of
drug discovery can take years, the approach that can be
utilized here to find a predictable drug for SARS-CoV-2
is to use in silico protein-peptide docking studies of the
most variable target proteins in SARS-CoV-2, which is
spike protein from SARS-CoV-2 (Tahir ul Qamar et al.,
2020; Wu et al., 2020).
SARS-CoV-2 spike protein is responsible for controlling
some of the main functions of the virus and has a catalytic
domain that is highly conserved from the SARSCoV virus (Zhang et al., 2020). Some other functions
include the virus replication process which makes it
an ideal target in drug development (Das et al., 2020;
Ton et al., 2020). It has been computationally proven
that SARS-CoV-2 has a mechanism that is identical to
the SARS-CoV virus and has a high affinity for ACE-2
(Angiotensin Converting Enzyme-2) receptor (Xu et al.,
2020). Besides, there are structural similarities between
SARS-CoV-2 and SARS-CoV spike proteins, which
conservation is only 73% with most of the variability in
the area of host cell protein interaction (Hall & Ji, 2020).
Dermaseptin is an antiviral peptide produced by frogs
of the genus Phyllomedusa. The antiviral activity of
this peptide has been described for HSV-1, HSV-2, and
HIV-1, in which the virus envelope appears to be the
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preferred target of dermaseptin (Bergaoui, Zairi, et al.,
2013; Bergaoui, Zairi, et al., 2013; Mechlia et al., 2019).
Recently, derivatives of dermaseptin have also been
tested on coronavirus family computationally and show
the strongest antiviral activity (Mustafa et al., 2019).
Given these results, the affinity of several dermaseptin
derivatives for SARS-CoV-2 spike protein through in
silico was demonstrated.
METHODS
Preparation of the SARS-CoV-2 Spike Protein
Macromolecule
In this study, the macromolecule used was the spike
protein of SARS-CoV-2 obtained from Protein Data Bank
(http://www.rcsb.org/pdb) with PDB ID 6LZG (Wang
et al., 2020). The macromolecule was then prepared
by removing water molecules, adding polar hydrogen
atoms, and calculating Kollman’s partial charge.
Preparation of the Antiviral Peptide Molecules
In this study, the molecules used are dermaseptin-S4 and
dermaseptin-S9 antiviral peptide sequences which were
produced by frogs of the genus Phyllomedusa and have
been sequenced using PEPFOLD 3.5 (http://bioserv.
rpbs.univ-paris-diderot.fr/PEP-FOLD/) (Figure 1). PEPFOLD 3.5 is a server used to model peptide sequences
with amino acid counts between 5 and 50 into threedimensional conformation using the de novo method
(Lamiable et al., 2016; Maupetit et al., 2009; Shen et al.,
2014; Thévenet et al., 2012). The results of the peptide
molecular modeling were then used as input for proteinpeptide docking simulations.
The Simulations of Protein-Peptide Docking
In this study, HPEPDOCK was used to simulate proteinpeptide docking (Huang & Zou, 2007, 2008; Yan et al.,
2017; Zhou, Jin, et al., 2018; Zhou, Li, et al., 2018). The
two antiviral peptide molecules for docking simulations
were modeled and polar hydrogen atoms were added
using the de novo method. Then the protein-peptide
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complex type was selected by RMSD 4.0 Å grouping.
The shape of the Connolly point surface of the molecule
into different components including convex, concave,
and flat patch was produced through the HPEPDOCK
algorithm. HPEPDOCK optimized, refined, overhauled,
and re-selected the side chain interface from the top
10 candidate solutions. It also changed the relative
orientation of the molecule by limiting flexibility in
the side chains of the interacting surface and allowing
the movement of small and rigid objects. Analysis of
the results of protein-peptide docking simulations was
performed using Discovery Studio 2020 (Sharma, 2019;
Sharma et al., 2019).
Preparation of ACE-2 Receptor Macromolecule
In this study, ACE-2 receptor macromolecule was
downloaded from Protein Data Bank (http://www.rcsb.
org/pdb) with PDB ID 2AJF (Li et al., 2005). This
receptor macromolecule was prepared by removing
water molecules, adding polar hydrogen atoms, and
calculating Kollman’s partial charge.
The Simulations of Protein-Protein Docking
In this study, pyDockWEB was also used to simulate
docking of protein-protein between the two peptide
complexes resulting from protein-peptide docking to
ACE-2 receptor (Ahuja & Singh, 2016; Sable & Jois,
2015; Jiménez-García et al., 2013). The RMSD 4.0 Å
grouping was used and the protein-protein complex type
was selected. The surface representation of the Connolly
point from the molecule into different components
such as convex, concave, and flat patch was generated
through the pyDockWEB algorithm. pyDockWEB
optimized, refined, overhauled, and re-selected the side
chain interface from the top 10 candidate solutions. It
also changed the relative orientation of the molecule by
limiting flexibility in the side chains of the interacting
surface and allowing the movement of small and rigid
objects. The suitability of the system was verified by
visualization observations using Discovery Studio 2020
(Sharma, 2019; Sharma et al., 2019).

Dermaseptin-S4			
(ALWMTLLKKVLKAAAKAALNAVLVGANA)

Dermaseptin-S9			
(GLRSKIWLWVLLMIWQESNKFKKM)

Figure 1. The molecular structure of the antiviral peptides used in this study
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RESULTS AND DISCUSSION

Based on the visualization of protein-peptide docking
simulation results, dermaseptin-S4 peptide and
dermaseptin-S9 peptide show different conformational
molecular interactions with the active site of SARSCoV-2 spike protein. However, the two peptide molecules
can occupy the polar patch in the active binding site of
SARS-CoV-2 spike protein macromolecule (Figure 2).
This phenomenon can occur because the HPEPDOCK
algorithm allows peptide molecules to move freely
without rigid bonds to the molecular docking system
used. Overall, interactions formed by dermaseptin-S9
peptide were more numerous than dermaseptin-S4
peptide, with eighteen interactions including nine
hydrogen bonds (with Asn370, Ser375, Thr376, Lys378,
Gly404, Asp405, and Gln414), eight hydrophobic
interactions (with Tyr369, Ala372, Pro384, Lys386, and
Arg408), and one electrostatic interaction (with Arg408).
		
On the other hand, dermaseptin-S4 peptide only forms
seven interactions consisting of six hydrogen bonds (with
Leu335, Pro337, Phe338, Asn343, Val367, and Ser373)
and one hydrophobic interaction (with Phe338) (Table
2). In general, dermaseptin-S4 and dermaseptin-S9
peptide molecules have different interactions with the
active site area of SARS-CoV-2 spike protein. However,
the binding site of dermaseptin-S9 peptide molecule is
predicted to be more potent as a location for attaching
inhibitory molecules suitable for the SARS-CoV-2
protein spike macromolecule, especially compounds
with large molecular weights. This is due to amino acid
residues in the area more than in the binding location of

The Simulations of Protein-Peptide Docking
The two antiviral peptides produced by frogs of the
genus Phyllomedusa that have been modeled with PEPFOLD 3.5 server were then identified and evaluated
for their affinity and interaction with the spike protein
macromolecule of SARS-CoV-2 that has been prepared
through protein-peptide docking simulations using the
HPEPDOCK algorithm. The results of protein-peptide
docking simulations in Table 1 show that dermaseptin-S9
peptide has the best affinity with the active binding site of
SARS-CoV-2 spike protein compared to dermaseptin-S4
peptide, with binding free energy values of −792.93 kJ/
mol and −692.43 kJ/mol, respectively. This phenomenon
proves that there is a promising sign of dermaseptin-S9
peptide as an inhibitor of SARS-CoV-2 spike protein
because it has strong binding and interactions in the
active site area of the target macromolecule. Through
protein-protein docking simulations, the ability of
the peptide-protein complex that has been formed in
inhibiting its attachment to the ACE-2 (Angiotensin
Converting Enzyme-2) receptor macromolecule was
further demonstrated.
Table 1. The affinity of the antiviral peptide molecules
against the SARS-CoV-2 spike protein macromolecule
Peptide molecule
Dermaseptin-S4

Binding free energy (kJ/mol)
−692.43

Dermaseptin-S9

−792.93

67

Figure 2. The poses of Dermaseptin-S4 peptide (yellow) and Dermaseptin-S9
peptide (blue) in the binding site area of SARS-CoV-2 spike protein macromolecule
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Table 2. The interactions formed between antiviral peptide molecules and SARS-CoV-2 spike protein
macromolecule
Peptide molecule
Dermaseptin-S4

Number of interactions
7

Dermaseptin-S9

18

the dermaseptin-S4 peptide molecule. This phenomenon
is proven by the ability of the dermaseptin-S9 peptide
molecule to form strong and stable interactions with the
target macromolecules.
The dominant interaction of the peptide-protein complex
is hydrogen bonds, especially peptide molecules which
act as hydrogen bonds donors and amino acid residues in
the target macromolecule as hydrogen bond acceptors.
Most hydrogen bonds between peptide molecules
and protein macromolecules are relatively strong,
with average bond lengths starting at 3 Å. In addition
to hydrogen bonds, there are also contributions from
hydrophobic interactions and interestingly there are
electrostatic interactions in dermaseptin-S9 peptide
complex. It can be predicted that hydrogen bonds,
hydrophobic interactions, and electrostatic interactions
play an important role in stabilizing peptide-protein
complexes.
The Simulations of Protein-Protein Docking
Thereafter, to ensure the ability of each peptide-protein
complex to prevent the attachment of SARS-CoV-2 spike
protein macromolecule to the surface of ACE-2 receptor,
identification, evaluation, and exploration were carried
out using the protein-protein docking methods. The best
affinity with strong and stable molecular interactions of
the peptide-protein complex is predicted to prevent the
entry of SARS-CoV-2 into cells and host tissues due to
their inability to reach ACE-2 receptor in the process of
SARS-CoV-2 infection signaling. It is also important
to observe amino acid residues that play an important
role in inhibiting the formation of molecular interactions
between the binding site of SARS-CoV-2 spike protein
macromolecule and the surface area of ACE-2 receptor.
Based on the results of the protein-protein docking
simulations in Table 3, dermaseptin-S4 peptide complex
and dermaseptin-S9 peptide complex have positive
total energy, with values of 303.87 kJ/mol and 517.85

Amino acid residues
Leu335, Pro337, Phe338, Asn343, Val367, Ser373
Tyr369, Asn370, Ala372, Ser375, Thr376, Lys378,
Pro384, Lys386, Gly404, Asp405, Arg408, Gln414
kJ/mol, respectively. Interestingly, dermaseptin-S9
peptide complex has a better total energy value than
dermaseptin-S9 peptide complex due to the contribution
of electrostatic interactions and van der Waals interactions
that exist between the protein-protein complexes
formed. This phenomenon shows that both dermaseptin
peptide molecules bound to SARS-CoV-2 spike protein
macromolecule can prevent the attachment of ACE-2
receptor so that the infection signal can be prevented.
The interaction between peptide-protein complexes in
both dermaseptin peptide molecules is also dominated
by unfavorable interactions. Given this interaction, it is
thought that the formation of infection signals in SARSCoV-2 will not occur.
CONCLUSION
The dermaseptin-S9 peptide molecule can form a stable
and strong molecular interaction with the active site of the
binding of SARS-CoV-2 spike protein macromolecule.
This is indicated by the best affinity value compared to
dermaseptin-S4 peptide molecule, with a free binding
energy value of −792.93 kJ/mol. Dermaseptin-S9
peptide molecule is also able to prevent the attachment
of SARS-CoV-2 spike protein macromolecule to the
surface of ACE-2 receptor because it has positive total
energy, with a value of 517.85 kJ/mol. Based on the
results of this study it was proven that dermaseptin-S9
peptide molecule has the potential as a candidate for
SARS-CoV-2 spike protein macromolecule inhibitor in
controlling COVID-19 disease.
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Table 3. The total energy of the peptide-protein complexes against ACE-2 receptor macromolecule

Dermaseptin-S4 + SARS-CoV-2 Spike Protein

Electrostatics
(kJ/mol)
183.17

Desolvation
(kJ/mol)
42.74

van der Waals
(kJ/mol)
77.96

Total energy
(kJ/mol)
303.87

Dermaseptin-S9 + SARS-CoV-2 Spike Protein

176.69

85.20

255.96

517.85

Peptide-protein complex
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